Cogstate (CGS) AGM 2026 presentation summary

Financial performance review

• FY26 sales contracts $89.0m, up 116%; 90 trial starts vs 35; contracted revenue $118.5m, including $48.3m for FY27, up 54%.

• FY26 revenue $60.9m, up 15%; gross profit $35.4m at 58% margin, with 2H26 margin of 62%; PBT $16.1m, up 16%; cash $34.8m and no debt.

• 1Q27 net sales contracts $25.13m, up 17% YoY; nine new trials included four Phase 3 trials.

• Contracted revenue reached $143.7m, with $56.8m expected to be recognised in FY27; FY28 contracted revenue was $39.7m.

• Clinical trials backlog run-off totalled $132.3m at 30 September 2026, versus $107.1m at 30 June 2026.

Board and executive committee updates

• Martyn Myer was Non-Executive Chairman; Brad O'Connor was Managing Director and CEO.

• Ingrid Player chaired Audit, Risk & Compliance; Kim Wenn chaired Remuneration and Nomination; committee memberships also included Richard Mohs and Darryl Inns.

Dividend announcements

• FY26 annual dividend increased to A$0.04 per share, fully franked; payout ratio was ~40% of after-tax profit, within the 20%–50% target range.